טוען...
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
Estrogen, progesterone, and HER2 receptor-negative triple-negative breast cancers encompass the most clinically challenging subtype for which targeted therapeutics are lacking. We find that triple-negative tumors exhibit elevated MYC expression, as well as altered expression of MYC regulatory genes,...
שמור ב:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
The Rockefeller University Press
2012
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3328367/ https://ncbi.nlm.nih.gov/pubmed/22430491 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20111512 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|